Wanted pages
From Glioblastoma Treatments
Jump to navigationJump to search
List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.
Showing below up to 50 results in range #201 to #250.
- Increased side effects when administered in the morning; however, these are generally manageable with other therapies. (1 link)
- Initial report on recurrent GBM patients showed a PFS-6 value of 48% (1 link)
- Initial results indicate a need for dosage optimization to balance efficacy and side effects (1 link)
- Injection site reactions, fatigue, mild fever, allergic reactions (rare) (1 link)
- Intracranial edema, nausea, lymph node infection (rare and manageable) (1 link)
- Investigated primarily in hepatitis and cirrhosis; small studies in cancers such as acute lymphoblastic leukemia, prostate cancer, breast cancer, head and neck cancer, and hepatocellular carcinoma (1 link)
- Investigational, including early clinical trials (1 link)
- Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation (1 link)
- Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity (1 link)
- Localized discomfort, potential damage to surrounding healthy tissue (1 link)
- Low (1 link)
- Low blood counts, pulmonary problems, infection, and seizures for Gliadel (1 link)
- Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months (1 link)
- Malnourished advanced cancer patients: 110 days; adequately nourished patients: 350 days; chemotherapy alone in non-small cell lung cancer: 39% one-year survival (1 link)
- Median DFS of 11.9 months for the vaccine group vs. 5.6 months for the placebo group; HR: 0.52 (95% CI: 0.33-0.82), p = 0.005 (1 link)
- Median OS for glioblastoma patients not taking Keppra: 16.7 months (1 link)
- Median OS for glioblastoma patients taking Keppra during chemotherapy: 25.7 months (1 link)
- Median OS not reached for the vaccine group vs. 22.2 months for the placebo group; HR: 0.55 (95% CI: 0.35-0.87), p = 0.011 (1 link)
- Median PFS for patients not taking Keppra: 6.7 months (1 link)
- Median PFS for patients taking Keppra: 9.4 months (1 link)
- Median overall survival for GBM is typically 15-17 months from diagnosis (1 link)
- Median overall survival of 19.3 months from randomization (22.4 months from surgery) for newly diagnosed GBM patients; 13.2 months from relapse for recurrent GBM (1 link)
- Median progression-free survival of 6.2 months in the DCVax-L arm, compared to 7.6 months in the placebo group, though this difference was not statistically significant (1 link)
- Median survival for recurrent GBM typically less than one year (1 link)
- Median survival of 42.6 weeks (~9.8 months) in recurrent GBM; Median survival of 23.8 months in newly diagnosed GBM when combined with the Stupp protocol (1 link)
- Median survival with Tarceva addition: ranges from 15.3 to 19.3 months in studies, though one study showed only 8.6 months (1 link)
- Median survival with enzyme-inducing anticonvulsants: 11 months (1 link)
- Median survival with standard Temodar protocol: approximately 14.1 months (1 link)
- Metformin is under investigation for its potential anti-cancer properties in glioblastoma, particularly its effects on glioma stem cells. Studies focus on its ability to inhibit cell proliferation and induce apoptosis in cancerous cells. (1 link)
- Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression (1 link)
- Mostly preclinical, involving cell culture studies and some early-stage human research (1 link)
- Myelosuppression, including neutropenia and lymphopenia; some instances of serious adverse events possibly related to VAL-083 (1 link)
- N/A (Established treatment modality) (1 link)
- Nausea, constipation (obstipation); side effects commonly resolved after one month of therapy (1 link)
- Nausea, vomiting, fatigue, myelosuppression, lymphopenia (1 link)
- Nephrotoxicity, ototoxicity, and neurotoxicity (1 link)
- No known toxic side effects (1 link)
- Not applicable; current recommendations favor omega-3 fatty acids for potential CNS benefits (1 link)
- Not applicable; current research focuses on biochemical effects and prevention metrics like PSA doubling time in prostate cancer (1 link)
- Not applicable; current research has not progressed to detailed assessments of progression-free survival in cancer patients. (1 link)
- Not applicable; current research is primarily in preclinical stages focusing on cellular mechanisms (1 link)
- Not applicable; direct impacts on progression-free survival in cancer patients are not yet established (1 link)
- Not applicable; emphasis on omega-3 fatty acids due to better CNS penetration and cost-effectiveness (1 link)
- Not applicable; ongoing research into potential impacts on overall survival in cancer patients (1 link)
- Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients (1 link)
- Not applicable; ongoing studies aim to determine the potential impacts on tumor progression (1 link)
- Not applicable; preclinical focus does not include progression-free survival metrics (1 link)
- Not applicable; preclinical studies do not measure overall survival (1 link)
- Not applicable; research is still in preclinical stages, focusing on cellular and animal models (1 link)
- Not applicable; studies are ongoing to determine its effect on disease progression in preclinical models (1 link)
